Filtros de búsqueda

Lista de obras de

A new dawn in cardiovascular protection: total cardiovascular risk: rigorous treatment of risk factors. Introduction

artículo científico publicado en 2008

Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE Study

artículo científico publicado en 2004

All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy

artículo científico publicado en 2010

Angiotensin AT2-receptor stimulation improves survival and neurological outcome after experimental stroke in mice

artículo científico publicado en 2016

Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study

artículo científico publicado en 2005

Aortic valve sclerosis and albuminuria predict cardiovascular events independently in hypertension: a losartan intervention for endpoint-reduction in hypertension (LIFE) substudy

artículo científico publicado en 2005

Are coronary revascularization and myocardial infarction a homogeneous combined endpoint in hypertension trials? The Losartan Intervention For Endpoint reduction in hypertension study.

artículo científico publicado en 2010

Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke

artículo científico publicado en 2008

Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future?

artículo científico publicado en 2007

Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial).

artículo científico publicado en 2009

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients

artículo científico publicado en 2008

Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk

artículo científico publicado en 2002

Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study

artículo científico publicado en 2005

Cardiovascular disease risk factors: epidemiology and risk assessment.

artículo científico publicado en 2010

Cardiovascular events during differing hypertension therapies in patients with diabetes

artículo científico publicado en 2010

Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-Hypertension-2.

artículo científico publicado en 2004

Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study

artículo científico publicado en 2005

Cardiovascular morbidity and mortality in hypertensive patients with lower versus higher risk: a LIFE substudy

artículo científico publicado en 2005

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

artículo científico publicado en 2002

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

artículo científico publicado en 2002

Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study

artículo científico publicado en 2004

Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study

artículo científico publicado en 2002

Change in pulse pressure/stroke index in response to sustained blood pressure reduction and its impact on left ventricular mass and geometry changes: the life study

artículo científico publicado en 2008

Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study

artículo científico publicado en 2002

Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study

artículo científico publicado en 2002

Clinical impact of 'in-treatment' wall motion abnormalities in hypertensive patients with left ventricular hypertrophy: the LIFE study

artículo científico publicado en 2008

Combination of the electrocardiographic strain pattern and albuminuria for the prediction of new-onset heart failure in hypertensive patients: the LIFE study

artículo científico publicado en 2008

Compound 21, the first orally active, selective agonist of the angiotensin type 2 receptor (AT2): implications for AT2 receptor research and therapeutic potential

artículo científico publicado en 2009

Contrasting hemodynamic mechanisms of losartan- vs. atenolol-based antihypertensive treatment: a LIFE study

artículo científico publicado en 2012

Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study

artículo científico publicado en 2002

Correlates of pulse pressure reduction during antihypertensive treatment (losartan or atenolol) in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE study).

artículo científico publicado en 2002

Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial

artículo científico publicado en 2005

Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).

artículo científico publicado en 2005

Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA).

artículo científico publicado en 2005

Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB.

artículo científico publicado en 2010

Direct angiotensin II type 2 receptor stimulation ameliorates insulin resistance in type 2 diabetes mice with PPARγ activation

artículo científico publicado en 2012

Direct stimulation of angiotensin II type 2 receptor enhances spatial memory

artículo científico publicado en 2011

Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy

artículo científico publicado en 2004

Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study

artículo científico publicado en 2006

Echocardiographic wall motion abnormalities in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE Study

artículo científico publicado en 2003

Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE study

artículo científico publicado en 2010

Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial

artículo científico publicado en 2008

Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study

artículo científico publicado en 2003

Effect of losartan versus atenolol on aortic valve sclerosis (a LIFE substudy).

artículo científico publicado en 2004

Effect of lower on-treatment systolic blood pressure on the risk of atrial fibrillation in hypertensive patients

artículo científico

Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy

artículo científico publicado en 2009

Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second [...]

artículo científico publicado en 2008

Effects of atenolol or losartan on fibrinolysis and von Willebrand factor in hypertensive patients with left ventricular hypertrophy

artículo científico publicado en 2009

Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study

artículo científico publicado en 2008

Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy

artículo científico publicado en 2002

Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial

artículo científico publicado en 2003

Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study

artículo científico publicado en 2009

Electrocardiographic strain pattern and left ventricular diastolic function in hypertensive patients with left ventricular hypertrophy: the LIFE study

artículo científico publicado en 2006

Electrocardiographic strain pattern and prediction of cardiovascular morbidity and mortality in hypertensive patients

artículo científico publicado en 2004

Electrocardiographic strain pattern and prediction of new-onset congestive heart failure in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study

artículo científico publicado en 2005

Ethnic differences in electrocardiographic criteria for left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint

artículo científico publicado en 2002

Exercise and cardiovascular outcomes in hypertensive patients in relation to structure and function of left ventricular hypertrophy: the LIFE study

artículo científico publicado en 2009

Felodipine-metoprolol combination tablet: maintained health-related quality of life in the presence of substantial blood pressure reduction

artículo científico publicado en 2005

Four-group classification of left ventricular hypertrophy based on ventricular concentricity and dilatation identifies a low-risk subset of eccentric hypertrophy in hypertensive patients

artículo científico

Gender differences in regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy

artículo científico publicado en 2008

Generic and therapeutic substitution: a viewpoint on achieving best practice in Europe

artículo científico publicado en 2011

Greater regression of electrocardiographic left ventricular hypertrophy during hydrochlorothiazide therapy in hypertensive patients

artículo científico publicado en 2010

Higher pulse pressure/stroke volume index is associated with impaired outcome in hypertensive patients with left ventricular hypertrophy the LIFE study

artículo científico publicado en 2016

Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies

artículo científico publicado en 2005

Hypertension therapy with beta blocker plus diuretic. "We are at the point of leaving behind an era"

artículo científico publicado en 2005

Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study

artículo científico publicado en 2006

Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study).

artículo científico publicado en 2008

In-treatment midwall and endocardial fractional shortening predict cardiovascular outcome in hypertensive patients with preserved baseline systolic ventricular function: the Losartan Intervention For Endpoint reduction study

artículo científico publicado en 2010

In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study

artículo científico publicado en 2010

Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study

artículo científico publicado en 2008

Incidence of heart failure in relation to QRS duration during antihypertensive therapy: the LIFE study

artículo científico publicado en 2009

Influence of age, sex and blood pressure on the principal endpoints of the Nordic Diltiazem (NORDIL) Study

artículo científico publicado en 2002

Lack of regression of left ventricular hypertrophy is associated with higher incidence of revascularization in hypertension: The LIFE Study

artículo científico publicado en 2010

Left Ventricular Wall Stress-Mass-Heart Rate Product and Cardiovascular Events in Treated Hypertensive Patients: LIFE Study

artículo científico publicado en 2015

Left atrial systolic force in hypertensive patients with left ventricular hypertrophy: the LIFE study

artículo científico publicado en 2008

Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study

artículo científico publicado en 2008

Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study

artículo científico publicado en 2004

Metabolic syndrome, new onset diabetes, and new end points in cardiovascular trials

artículo científico publicado en 2006

Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study

artículo científico publicado en 2002

Mitral annular calcification and incident ischemic stroke in treated hypertensive patients: the LIFE study

artículo científico publicado en 2013

Non-peptide AT2-receptor agonists

artículo científico publicado en 2010

Pathophysiologic and therapeutic importance of tissue ACE: a consensus report

artículo científico publicado en 2002

Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study

artículo científico publicado en 2005

Persistence of left ventricular hypertrophy is associated with increased cardiovascular morbidity and mortality in hypertensive patients with lower achieved systolic pressure during antihypertensive treatment

artículo científico publicado en 2013

Physical activity and exercise lower blood pressure in individuals with hypertension: narrative review of 27 RCTs

artículo científico publicado en 2016

Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study

artículo científico publicado en 2007

Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study

artículo científico publicado en 2008

Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension study

artículo científico publicado en 2009

Preventing stroke in hypertensive patients at risk

artículo científico publicado en 2008

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

artículo científico publicado en 2005

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

artículo científico publicado en 2003

Prevention of stroke in patients with hypertension

artículo científico publicado en 2007

Prognostic significance of left ventricular diastolic dysfunction in patients with left ventricular hypertrophy and systemic hypertension (the LIFE Study).

artículo científico publicado en 2010

Prognostic significance of left ventricular mass change during treatment of hypertension

artículo científico publicado en 2004

Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE).

artículo científico publicado en 2009

Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study

artículo científico publicado en 2002

Prospects for the prevention of stroke

artículo científico publicado en 2006

Pulse pressure, left ventricular function and cardiovascular events during antihypertensive treatment (the LIFE study).

artículo científico publicado en 2009

Pulse pressure/stroke index and left ventricular geometry and function: the LIFE Study

artículo científico publicado en 2003

QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention for Endpoint Reduction in Hypertension Study

artículo científico publicado en 2004

QRS duration predicts sudden cardiac death in hypertensive patients undergoing intensive medical therapy: the LIFE study

artículo científico publicado en 2009

Racial Differences in Incident Heart Failure During Antihypertensive Therapy ⬇️

artículo científico publicado el 8 de febrero de 2011

Racial differences in incident atrial fibrillation among hypertensive patients during antihypertensive therapy

artículo científico publicado en 2014

Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line comb

artículo científico publicado en 2004

Reduction (TELMAR) as assessed by magnetic resonance imaging in patients with mild-to-moderate hypertension--a prospective, randomised, double-blind comparison of telmisartan with metoprolol over a period of six months rationale and study design

artículo científico publicado en 2003

Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study

artículo científico publicado en 2005

Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).

artículo científico publicado en 2005

Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study

artículo científico publicado en 2006

Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events

artículo científico publicado en 2004

Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial

artículo científico publicado en 2004

Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint Reduction (LIFE) study

artículo científico publicado en 2003

Relation of impaired left ventricular filling to systolic midwall mechanics in hypertensive patients with normal left ventricular systolic chamber function: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study

artículo científico publicado en 2004

Relationship of left atrial enlargement to persistence or development of ECG left ventricular hypertrophy in hypertensive patients: implications for the development of new atrial fibrillation

artículo científico publicado en 2010

Relationship of sudden cardiac death to new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy

artículo científico

Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial

artículo científico publicado en 2010

Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study

artículo científico publicado en 2002

Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA).

artículo científico publicado en 2005

Serum uric acid is associated with new-onset diabetes in hypertensive patients with left ventricular hypertrophy: The LIFE Study

artículo científico publicado en 2010

Sex differences in effects of valsartan administration on cardiovascular outcomes in hypertensive patients: findings from the Jikei Heart Study

artículo científico publicado en 2010

Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study

artículo científico publicado en 2004

Surrogate markers for cardiovascular disease: structural markers

artículo científico publicado en 2004

Systolic left ventricular function according to left ventricular concentricity and dilatation in hypertensive patients: the Losartan Intervention For Endpoint reduction in hypertension study

artículo científico publicado en 2013

Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers

artículo científico publicado en 2005

Telmisartan to prevent recurrent stroke and cardiovascular events

artículo científico publicado en 2008

The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes

artículo científico publicado en 2008

The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study

artículo científico publicado en 2003

The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study

artículo científico publicado en 2003

The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study

artículo científico publicado en 2005

The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study

artículo científico publicado en 2005

The impact of serum uric acid on cardiovascular outcomes in the LIFE study

artículo científico publicado en 2004

The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT1.

artículo científico publicado en 2009

Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention for Endpoint Reduction

artículo científico publicado en 2002

Utility loss and indirect costs following cardiovascular events in hypertensive patients: the ASCOT health economic substudy

artículo científico publicado en 2007

Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study

artículo científico

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda